Workshop on Engineering Immune Cells for Cancer Therapy

Workshop on Engineering Immune Cells for Cancer Therapy

A Pre-Conference Program; additional registration was required

CAR T treatments have led to improved outcomes for patients with hematologic malignancies. However, the same level of success has not been achieved in most solid tumors, and other immune cell types beyond T cells are also being explored preclinically and clinically. This workshop highlighted the multitude of cellular therapy approaches being applied for the treatment of cancer, including many T cell strategies, alternative immune cells, practical considerations and novel technologies.

Monday, Nov. 9, 2020*

9 a.m. - 2:55 p.m. EST

*Dates and times subject to change.  

Workshop Organizers

  • Christine Brown, PhD – City of Hope 
  • Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
  • Marco Ruella, MD – University of Pennsylvania 

SITC's Workshop in Engineering Immune Cells for Cancer Therapy is supported in part by grants from Bristol Myers Squibb and Genentech, a member of the Roche Group.

Program Schedule*

*Program schedule subject to change.  

9 a.m.  Introduction
Katy Rezvani, MD, PhD - The University of Texas MD Anderson Cancer Center
Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs 
9:05 a.m. Cellular Immunotherapy for Metastatic Cancers
Steven A. Rosenberg, MD, PhD - National Cancer Institute, National Institutes of Health
9:25 a.m. Adoptive Therapy Utilizing TILs
John Haanen, MD, PhD - Netherlands Cancer Institute
9:45 a.m.

Endogenous T cell Therapy for Solid Tumors Malignancies
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center
10:05 a.m. Session I Panel Discussion - Session I Speakers
10:20 a.m. Break
Session II: Novel Approaches to Enhance CAR T cell Therapy 
10:35 a.m. Next-generation CARS for Blood Cancers
Michael Hudecek, MD - University of Wuerzburg
10:55 a.m. Advancing Immunotherapy Platforms for the Treatment of Solid Tumors
Saul Priceman, PhD - City of Hope
11:15 a.m.

Understanding Resistance to CAR T-cell Therapy to Develop Next-generation Immunotherapies
Marco Ruella, MD - University of Pennsylvania
11:35 a.m. Session II Panel Discussion - Session II Speakers
11:50 a.m. Break
Session III: CAR-Based Strategies Beyond T Lymphocytes 
12:05 p.m. CAR NK cells for the Immunotherapy of Cancer
Katy Rezvani, MD, PhD - The University of Texas MD Anderson Cancer Center
12:25 p.m. The Development of CAR Macrophages and Monocytes for Cancer Immunotherapy
Michael Klichinsky, PharmD, PhD - Carisma Therapeutics
12:45 p.m. Engineering B cells to Produce Therapeutic Antibodies
Justin J. Taylor, PhD - Fred Hutchinson Cancer Research Center
1:05 p.m. Session III Panel Discussion - Session III Speakers
1:20 p.m. Break
Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic 
1:35 p.m.
The Evolving Process of Clinical CAR T Cell Manufacturing in the Academic Setting
Isabelle C. Riviere, PhD - Memorial Sloan Kettering Cancer Center
1:55 p.m. Allogeneic CAR T therapy for Cancer
Barbra J. Sasu, PhD - Allogene Therapeutics
2:15 p.m. Corona Madness: Flattening the Curve with CAR T
Carl H. June, MD - University of Pennsylvania
2:35 p.m. Session IV Panel Discussion - Session IV Speakers
2:50 p.m. Closing Remarks
Christine Brown, PhD - City of Hope

Target Audience

The target audience for this program includes basic scientists and clinical investigators from academic institutions, venture capital, industry, and regulatory agencies. Additional audiences benefiting from this program include clinicians, graduate students, and postdoctoral fellows involved in cancer research and its translation into clinical practice, as well as those involved in manufacturing of cellular therapies.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Explain the status and direction of cellular therapies for cancer treatment
  • Identify highly relevant challenges and questions facing the translation of cellular therapies from preclinical to clinical settings
  • Describe cellular therapies employing immune cells other than T cells
  • Summarize novel technologies that are enabling broader application of cellular therapies for cancer
This program is not eligible for continuing education credit.
Workshop_2019.jpg
workshop_2019_2.jpg